熱門資訊> 正文
Genfit S.A. GAAP每股收益-0.20欧元，收入3567万欧元
2025-09-23 12:52
- Genfit S.A. press release (OTCPK:GNFTF): 1H GAAP EPS of -€0.20.
- Revenue of €35.67M (-41.7% Y/Y).
- Cash and cash equivalents totaled €107.5 million as of June 30, 2025, excluding the €26.5 million milestone invoiced in May 2025 (received in July 2025) upon pricing and reimbursement approval of Iqirvo® (elafibranor) in three major European countries.
- "We expect that our existing cash and cash equivalents will enable us to fund our operating expenses and capital expenditure requirements beyond the end of 2028, enabling the Company to further develop its pipeline focused on Acute-on-Chronic Liver Failure and support general corporate purposes. "
More on Genfit
- Seeking Alpha’s Quant Rating on Genfit
- Historical earnings data for Genfit
- Financial information for Genfit
推薦文章
華盛早報 | 達成共識！貝森特「不再考慮」對中國加徵100%關税，美股三大股指期貨齊漲！賽力斯今起招股
一周財經日曆 |下周重磅事件搶先看：美聯儲利率決議、科技巨頭財報密集來襲
港股周報 | 利好不斷！恆指重回26000點；高息股獲資金青睞！農業銀行錄得12連漲
一周IPO | 八馬茶業、滴普科技預計下周二上市；傳賽力斯最快下周一招股
美股機會日報 | 9月CPI低於預期！三大股指期貨直線拉昇；英特爾盤前大漲超5%
營收創新高、利潤暴跌29%！馬斯克的AI豪賭能撐起特斯拉的未來嗎？
甲骨文兩日跌超10%，「超預期宏偉目標」不再「吃香」？
小馬智行、文遠知行回港上市，迎Robotaxi 的deepseek時刻？
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
